OTCMKTS:MCUJF Medicure 11/25/2024 Earnings Report $0.62 +0.02 (+2.89%) As of 05/12/2025 01:24 PM Eastern Earnings History Medicure EPS ResultsActual EPS$0.05Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMedicure Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMedicure Announcement DetailsQuarterDate11/25/2024TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Medicure Earnings HeadlinesMedicure Inc. (MCUJF) Q4 2024 Earnings Call TranscriptApril 30, 2025 | seekingalpha.comMedicure Inc. Reports 2024 Financial Results with Increased Revenue but Net LossApril 25, 2025 | tipranks.comFed’s New Plan: They Could Freeze Your AccountThe Fed's Plan to Control Your Money Is Live! While everyone is focused on tariffs and inflation, the Federal Reserve is quietly rolling out a new program that could give them unprecedented control over your bank account. This isn't a rumor—it's all laid out in Federal Reserve Docket No. OP-1670, a 93-page document that reveals their plan to monitor and control your finances to shield yourself. In this free Wealth Defense Guide, we'll show you 3 simple steps to shield your money from the Fed's overreach and keep your savings safe.May 14, 2025 | Priority Gold (Ad)Medicure Expands U.S. Pharmacy Business with West Olympia AcquisitionApril 11, 2025 | tipranks.comMedicure Completes Strategic Acquisition of Gateway Medical PharmacyMarch 11, 2025 | tipranks.comMedicure Expands Pharmacy Business with Gateway AcquisitionFebruary 18, 2025 | tipranks.comSee More Medicure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email. Email Address About MedicureMedicure (OTCMKTS:MCUJF), a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.View Medicure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles AppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upcoming Earnings Copart (5/15/2025)NetEase (5/15/2025)Applied Materials (5/15/2025)Mizuho Financial Group (5/15/2025)National Grid (5/15/2025)Walmart (5/15/2025)Alibaba Group (5/15/2025)Deere & Company (5/15/2025)Palo Alto Networks (5/19/2025)PDD (5/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
